Why did the ResMed share price finish down in FY22?

It was a year of highs and lows for the healthcare company.

| More on:
A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Resmed shares finished down in FY22 after a year of highs and lows
  • The company's share price closesly tracked general weakness in healthcare sector shares in FY22
  • The Resmed share price has slipped more than 5% into the red over the past 12 months

The Resmed Inc (ASX: RMD) share price had a year of ups and downs on the market, finishing around 6% in the red.

Resmed shares reached a 52-week high of $40.28 on 23 August and, after heading sideways for a short time afterwards, began their journey south.

In broader market moves, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down more than 7% year to date.

What happened with the Resmed share price in FY22?

Shares in the sleep treatment company saw a series of paper losses last financial year.

After falling off its 52-week high, outlined above, the Resmed share price continued its descent and finished at a 52-week low of $27.63 on 27 May.

It was a fairly quiet year in terms of news for the company so it was no surprise to see its share price track closely to the wider healthcare sector's performance.

Healthcare shares as a whole weakened around September 2021. Losses were compounded in the January selloff and there's been a slow recovery ever since.

As seen on the chart below, the healthcare index and the Resmed share price both entered a period of peaks and troughs throughout the year.

TradingView Chart

The pair have tracked remarkably closely over the past 12 months to finish down in FY22.

Despite its share price struggles in FY22, analysts are still bullish on Resmed shares. Morgans rates the company a buy and says it liked the outlook on Resmed's "unique, patient-centric, connected-care digital platform".

In all, eight brokers are saying Resmed shares are a buy whereas six say the company's shares are a hold right now, according to Bloomberg data.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »